Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q1 2021 Earnings Presentation
8 slides from Puma Biotechnology's earnings presentation, May 6, 2021
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update May 6, 2021
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: PUMA's Pharmacy and Distributor Network
PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria health Accredo CVS ONCO 360 Patients Optum / Diplomat Biologics Sites of Care Specialty Distributor Network (SD) Academic hospitals McKesson Community hospitals ASD/Oncology supply Physician Practices Cardina
Slide 4: ~$46 Million Net NERLYNX Revenue in Q1'21
~$46 Million Net NERLYNX Revenue in Q1’21 Quarterly Net Revenue (in $MM) 61.1 58.7 52.6 53.8 53.5 50.8 50.0 48.6 48.8 49.3 45.6 45.8 36.0 20.1 6.1 '2 017 '2 017 '2 018 '2 018 '2 018 '2 018 '2 019 '2 019 '2 019 '2 019 '2 020 '2 020 '2 020 '2 020 '2 021 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Cop
Slide 5: 3,247 Ex-factory Bottles were Sold in Q1'21
3,247 Ex-factory Bottles were Sold in Q1’21 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 3,247 2,137 675 '2 017 '2 017 '2 018 '2 018 '2 018 '2 018 '2 019 '2 019 '2 019 '2 019 '2 020 '2 020 '2 020 '2 020 '2 021 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 6: ~38% of Patients in Q1'21 Started at a Reduced Dose
~38% of Patients in Q1’21 Started at a Reduced Dose % of patients starting at reduced dose 42.4% 37.7% 32.8% 30.4% 30.8% 28.4% 19.0% 12.0% 10.7% 6.3% 6.8% 2.9% 3.8% 1.8% 2.5% 7 7 8 8 8 8 9 9 9 9 0 0 0 0 1 201 201 201 201 201 201 201 201 201 201 202 202 202 202 202 Q3' Q4' Q1' Q2' Q3' Q4' Q1' Q2' Q3'
Slide 7: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Singapore Australia / SE Asia • 2020 – Ext. Adj. in Brunei, Malaysia, New • Q2 2021 – Malaysia, Brunei, New Zealand Zealand Israel • 2020 – Approved in E
Slide 8: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update May 6, 2021